ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
14 announcements with these filters
Acutaas Chemicals Limited has announced the re-appointment of Ram Mohan Lokhande as Executive Director and Anita Bandyopadhyay as Non-Executive Independent Director for a 60-month term.
Acutaas Chemicals will acquire 100% of Enchem Ami Organics Private Limited for Rs. 1 Lakh, making it a wholly owned subsidiary.
Acutaas Chemicals will acquire 100% equity stake in step-down subsidiary Enchem Ami Organics for Rs. 1 Lakh, making it a direct wholly-owned subsidiary.
Acutaas Chemicals Limited conducted its 19th Annual General Meeting on September 24, 2026, where shareholders transacted various ordinary and special business items.
Acutaas Chemicals Limited has received a patent from the Indian Patent Office for a process to prepare 2,4-dimethylthiophenol. The company now holds 11 patents.
Acutaas Chemicals Limited inaugurated a new state-of-the-art Pilot Plant at Unit 1 in Sachin, Surat. The facility supports R&D for high potency active pharmaceutical ingredients.
Acutaas Chemicals delivered a robust Q1 FY27 with 59.1% revenue growth, fueled by strong CDMO and Advanced Pharmaceutical Intermediates (API) performance.
Acutaas Chemicals delivered strong Q1 FY27 results with 59% YoY revenue growth. Management is focused on scaling high-margin Pharma Intermediates and CDMO segments while maintaining operational efficiencies.
Acutaas Chemicals Ltd reported revenue from operations of ₹329.7 Cr (+59.1% YoY) and net profit of ₹75 Cr (+70.5% YoY) for Q1 FY27.
Acutaas Chemicals delivered record FY26 results with Revenue of ₹13,394 Mn and PAT of ₹3,564 Mn, driven by expansion in pharmaceutical and semiconductor segments.
Acutaas Chemicals delivered record FY26 performance with ₹1,339.4cr revenue and ₹356.4cr PAT, driven by strong CDMO business and portfolio reshuffling towards high-value pharmaceutical intermediates.
Acutaas Chemicals delivered strong performance in Q4 FY26, with revenue up 40% and PAT doubling, driven by the high-margin CDMO business and specialty chemicals recovery despite supply chain disruptions.
Acutaas Chemicals reported strong Q4FY26 results with 40.3% YoY revenue growth and record PAT margins of 31%. Strategy focuses on Battery Chemicals, Semiconductors, and Pharma CDMO.
Acutaas Chemicals Ltd reported revenue from operations of ₹432.8 Cr (+40.3% YoY) and net profit of ₹134.3 Cr (+114.2% YoY) for Q4 FY26.